Biologics

Question 1

Osimertinib

Answer 1

EGFR TKI for NSLC
ADAURA trial: improved disease-free survival for stage IB-IIIA and EGFR+ but no FDA approval for neoadj or adjuvant yet

Question 2

nintedanib

Answer 2

Tx UIP/IPF. Along with perfinidone slows FVC decline by 50% over 1 year
(VEGF, FGF, PDGF)

Question 3

Imatinib

Answer 3

Gleevec - targets cKit TK-r to treats GIST tumor (from pacemakers of myenteric plexus aka interstitial cells of Cajal), bulky tumors may get gleevec then surgery

Question 4

Erlotinib
Gefitinib

Answer 4

EGFR TKI used for EGFR+ Stage IV NSLC (with chemo either as definitive or neoadjuvant if gets downstaged)

Question 5

durvalumab
Pembrolizumab
Atezolizumab

Answer 5

Target PD-L1
Uses:

Nonsurgical NSCLC with >50% PD1/PD-L1 and “extensive” small cell ==> survival (1st line)

With platinum C+RT for adeno

With platinum-etoposide for small cell lung

Question 6

Rituximab

Answer 6

CD20 B cells
treats NSIP (along with steroids and cyclophosphamide)

tx PTLD after lung txp

Question 7

Daclizumab
Basiliximab

Answer 7

Induction after OHT: CD25 block IL-2 receptors

Question 8

trastuzumab

Answer 8

Her2-neu positive esophageal cancers (adeno)
chemo + (survival benefit of trastuzamab) in stage 4